公开(公告)号：US20240382600A1

公开(公告)日：2024-11-21

申请号：US18687615

申请日：2022-08-30

Applicant: Novartis AG

Inventor： Emilie CHAPEAU ,  Patrick CHENE ,  Pascal FURET ,  Laurence KIEFFER ,  Rainer MACHAUER ,  Anne PICARD ,  Tobias SCHMELZLE ,  Holger SELLNER ,  Nicolas SOLDERMANN ,  Markus VOEGTLE ,  Markus WARTMANN

IPC: A61K47/54 ,  A61K47/55 ,  C07D405/14 ,  C07D417/12

Abstract: The present disclosure relates to a conjugate comprising a YAP/TAZ-TEAD Protein Protein Interaction Inhibitor (PPII) linked to a Ligase Binder via a linker, or a pharmaceutically acceptable salt thereof, as well as methods of using such conjugates.

公开(公告)号：US20240358720A1

公开(公告)日：2024-10-31

申请号：US18687599

申请日：2022-08-30

Applicant: Novartis AG

Inventor： Emilie CHAPEAU

IPC: A61K31/635 ,  A61P13/12 ,  A61P35/00

CPC classification number: A61K31/635 ,  A61P13/12 ,  A61P35/00

Abstract: The invention relates to a TEAD inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, wherein the TEAD inhibitor is administered on each of the first 3 days of a 7 day treatment cycle, and wherein the treatment comprises at least two treatment cycles.

公开(公告)号：US20240374571A1

公开(公告)日：2024-11-14

申请号：US18687616

申请日：2022-08-30

Applicant: Novartis AG

Inventor： Emilie CHAPEAU ,  Laurent L'EPICIER-SANSREGRET ,  Tobias SCHMELZLE

IPC: A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61P35/00

Abstract: The invention relates to a pharmaceutical combination comprising a TEAD inhibitor in combination with a first and optionally a second therapeutically active agent. The present invention also relates to methods of treating cancer involving administering to a subject in need thereof the TEAD inhibitor in combination with the first and optionally the second therapeutically active agent.